{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:17:23Z","timestamp":1768551443867,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clml.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:12:48Z","timestamp":1653325968000},"page":"744-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-5212","authenticated-orcid":false,"given":"Ryan J.","family":"Stubbins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Mabilangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi S","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta K","family":"Preiksaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthea C","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.05.006_bib0001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"DeStefano","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.05.006_bib0002","doi-asserted-by":"crossref","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clml.2022.05.006_bib0003","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/TP.0000000000002146","article-title":"The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single center experience","volume":"102","author":"Peters","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2022.05.006_bib0005","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1080\/10428194.2020.1808206","article-title":"Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes","volume":"61","author":"Stubbins","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.006_bib0006","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.006_bib0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.16304","article-title":"Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder","volume":"189","author":"Jain","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.05.006_bib0008","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0009","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1600-6143.2005.00776.x","article-title":"Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience","volume":"5","author":"Trofe","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2022.05.006_bib0010","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0011","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1080\/10428190802239162","article-title":"Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant","volume":"49","author":"Oton","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0013","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0014","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.006_bib0015","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/lt.26034","article-title":"Post-transplant lymphoproliferative disorders after liver transplantation: a retrospective cohort study including 1954 transplants","volume":"27","author":"Tajima","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clml.2022.05.006_bib0016","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2022.05.006_bib0017","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.006_bib0018","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.clml.2022.05.006_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fonc.2020.00614","article-title":"Prognostic value of tumor-infiltrating lymphocytes differs depending on lymphocyte subsets in esophageal squamous cell carcinoma: an updated meta-analysis","volume":"10","author":"Hao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.05.006_bib0021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.23398","article-title":"CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy","volume":"88","author":"Keane","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.05.006_bib0022","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3109\/10428190903315713","article-title":"Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors","volume":"50","author":"Richendollar","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.006_bib0023","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1002\/cam4.2394","article-title":"PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: an inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories","volume":"8","author":"Schiefer","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.05.006_bib0024","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clml.2022.05.006_bib0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2013.095257","article-title":"The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the lunenburg lymphoma biomarker consortium","volume":"99","author":"Sander","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.006_bib0026","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41581-020-0321-6","article-title":"Digital pathology and computational image analysis in nephropathology","volume":"16","author":"Barisoni","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clml.2022.05.006_bib0027","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5500\/wjt.v6.i3.505","article-title":"Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders","volume":"6","author":"Morscio","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.clml.2022.05.006_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12307-018-00219-5","article-title":"The tumor microenvironment in post-transplant lymphoproliferative disorders","volume":"12","author":"Marcelis","year":"2019","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.clml.2022.05.006_bib0029","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3324\/haematol.2018.200105","article-title":"T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma","volume":"104","author":"Leivonen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.006_bib0030","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-07-0504","article-title":"Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses","volume":"13","author":"Chang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.05.006_bib0031","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2022.05.006_bib0032","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2014.110189","article-title":"Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP","volume":"100","author":"Coutinho","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.05.006_bib0033","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41379-018-0193-5","article-title":"PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program","volume":"32","author":"Li","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2022.05.006_bib0034","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","article-title":"T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab","volume":"17","author":"Wahlin","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:46:51Z","timestamp":1729856811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2152265022001665"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}